Lumida
/SPRY
⌘K
ARS Pharmaceuticals Inc

ARS Pharmaceuticals Inc

SPRY
$4.76USD-5.93%-0.30 today

MARKET CAP

473.4M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$5
$13

AI Summary

Stalk
Sell NowHigh

SPRY is in a confirmed Stage 4 decline with medium-term bearish bias reinforced by an active Support Failure pattern. Price remains below declining 9-, 21-, and 50-period EMAs, with rallies consistently rejected. No mean-reversion eligibility is present, and speculative execution favors an immediate Sell Now into resistance near the broken support cluster.

  • Q2 2026 revenue of $33.7M topped consensus by 7.5% on neffy demand
  • Neffy holds 5% US epinephrine share with 16,000 unique prescribers
  • Q2 net loss of $62.3M (-$0.63/share) missed estimates by 31%
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.3M$30,000$89.1M$84.3M
YoY %-97.7%+297063.3%-5.5%
P / Sales255.6x17710.0x12.1x13.6x
EV / Sales102.2x15425.3x12.6x15.7x
Gross Profit, Adj.$1.3M$30,000$88.2M$63.9M
YoY %-97.7%+293806.7%-27.6%
Margin %100.0%100.0%98.9%75.8%
EV / Gross Profit102.2x15425.3x12.7x20.7x
EBITDA, Adj.$-35.2M$-67.4M$-3.0M$-178.1M
YoY %-91.6%+95.5%-5828.1%
Margin %-2674.5%-224823.3%-3.4%-211.3%
EV / EBITDA-3.8x-6.9x-374.1x-7.4x
EBIT$-35.5M$-67.5M$-3.1M$-179.4M
YoY %-90.1%+95.4%-5720.6%
Margin %-2698.8%-225066.7%-3.5%-212.9%
EV / EBIT-3.8x-6.9x-364.5x-7.4x
Net Income$-34.7M$-54.4M$8.0M$-171.3M
YoY %-56.8%+114.7%-2241.8%
Net Margin-2635.4%-181216.7%9.0%-203.3%
EPS (GAAP)-$0.87-$0.57$0.08-$1.74
YoY %+34.5%+114.0%-2275.0%